Project Grant R21AI182834
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Massachusetts a $632,994 Project Grant on February 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel antiviral therapies targeting Chikungunya virus (CHIKV) protease. The project, scheduled for completion by January 31, 2031, focuses on inhibiting the NSP2 protease from CHIKV (CHIKVp) through allosteric interactions with the...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Louisville Office of Research & Innovation a $684,921 Project Grant on September 24, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on the development of novel antiviral therapeutics targeting arthritogenic alphaviruses, with particular focus on Chikungunya virus and other Old World (OW) alphaviruses with pandemic...
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $227,115 to The Research Foundation for the State University of New York (RF-SUNY) at the University at Albany under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, issued February 3, 2026, with a completion date of January 31, 2028, funds research investigating the molecular function of adenine-rich (A-rich) regions within the Zika virus (ZIKV) 3' untranslated region...
- Federal Project Grant Award Summary The University of Louisville's Office of Research & Innovation received a $700,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) on September 4, 2025, with a completion date of August 31, 2029. This award supports fundamental biomedical research investigating a novel interaction between alphaviral capsid proteins and the host IRAK1 protein to...
- The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...
- This National Science Foundation (NSF) Mathematical and Physical Sciences (CFDA 47.049) project grant award of $1,500,000 supports research by Dr. Tamar Schlick of New York University and Dr. Alain Laederach of the University of North Carolina at Chapel Hill. The project aims to develop advanced computational tools to predict and control how viral protein synthesis is affected by programmed ribosomal frameshifting (PRF) - the mechanism by which viruses and human cells modify gene expression. Key...
- The American Type Culture Collection (ATCC) was awarded a $263,771 Project Grant from the Defense Threat Reduction Agency to conduct research titled "Genome-Wide Mapping (GWM) of Host Proteome: Pan Alphavirus Proteome Interactions for Discovery of Broad-Spectrum Countermeasures." The two-year project beginning October 12, 2021 aims to advance fundamental knowledge in scientific research combating weapons of mass destruction, as outlined in the agency's Scientific Research - Combating...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of North Carolina at Chapel Hill a Project Grant of $229,360 effective April 15, 2026, through March 31, 2028, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This exploratory R21 award funds research to identify and validate specific causal genes that regulate Chikungunya virus (CHIKV)-induced disease outcomes in humans. The research leverages...
- This Project Grant award of $892,050.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research at the University of Missouri at Kansas City (UMKC) to investigate how plant viruses modulate host chromatin dynamics and gene expression. The key objectives are to: Determine how the PEMV2 virus P26 protein induces chromatin compaction and alters host gene expression, potentially repressing...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of South Florida a $791,245 Project Grant effective May 6, 2026, through the Allergy and Infectious Diseases Research program (CFDA 93.855) to support fundamental biomedical research on placental antiviral defense mechanisms. The research, conducted through a collaborative effort between the Totary-Jain and Coyne laboratories, will elucidate how human trophoblasts (placental barrier cells) produce Type III...
MECHANISMS OF NOVEL HOST FACTORS IN ALPHAVIRUS INFECTION - ALPHAVIRUSES INCLUDE IMPORTANT AND EMERGING HUMAN PATHOGENS SUCH AS ENCEPHALITIC VIRUSES AND THE ARTHRITOGENIC CHIKUNGUNYA VIRUS. IN SPITE OF THEIR IMPORTANCE, THERE ARE CURRENTLY NO LICENSED ANTIVIRAL THERAPIES OR VACCINES. NEW APPROACHES AND INFORMATION ARE NEEDED TO DEVELOP ANTIVIRAL STRATEGIES. ALPHAVIRUSES ARE SMALL ENVELOPED VIRUSES WITH HIGHLY ORDERED STRUCTURES. THE NUCLEOCAPSID CORE CONTAINS THE PLUS-SENSE RNA GENOME PACKAGED WITHIN A CAPSID PROTEIN SHELL. THE CORE IS SURROUNDED BY THE VIRUS ENVELOPE, WHICH CONTAINS AN ORGANIZED ARRAY OF THE E2 AND E1 TRANSMEMBRANE PROTEINS. THE STRUCTURE AND FUNCTION OF THE VIRUS AND VIRAL PROTEINS HAVE BEEN EXTENSIVELY CHARACTERIZED. HOWEVER, THERE IS COMPARATIVELY LITTLE INFORMATION ON THE ROLE OF HOST PROTEINS IN THE VIRUS LIFE CYCLE, IN PARTICULAR FOR STEPS SUCH AS THE UNCOATING OF THE INCOMING VIRAL RNA DURING ENTRY, THE ASSEMBLY AND TRANSPORT OF THE NASCENT NUCLEOCAPSID, AND THE BUDDING OF VIRUS PARTICLES FROM THE PLASMA MEMBRANE. WE USED AN INNOVATIVE APPROACH TO IDENTIFY HOST PROTEINS THAT SPECIFICALLY ASSOCIATE WITH THE CAPSID/NUCLEOCAPSID DURING INFECTION. THE APPROACH IS BASED ON BIOTINYLATION OF THE CAPSID PROTEIN IN ALPHAVIRUS-INFECTED CELLS, CHEMICAL CROSSLINKING, SPECIFIC CAPSID PROTEIN RETRIEVAL UNDER DENATURING CONDITIONS, RELEASE OF CROSSLINKED CELLULAR PROTEINS, AND IDENTIFICATION OF SIGNIFICANT HOST PROTEIN ASSOCIATION BY MASS SPECTROMETRY. THESE CANDIDATE HOST FACTORS WERE EVALUATED BY SIRNA DEPLETION FOR EFFECTS ON INFECTION BY TWO DIFFERENT ALPHAVIRUSES. BASED ON EXTENSIVE PRELIMINARY RESULTS, WE PROPOSE TO CHARACTERIZE 4 HOST PROTEINS FOR THEIR PREVIOUSLY UNIDENTIFIED PRO-VIRAL ROLES IN ALPHAVIRUS INFECTION. THE SPECIFIC AIMS ARE: 1. DEFINE THE ROLE OF NOVEL HOST PROTEINS IN THE ALPHAVIRUS EXIT PATHWAY. DEPLETION OF TWO HOST PROTEINS INHIBITED ALPHAVIRUS SPREAD BUT DID NOT AFFECT PRIMARY INFECTION OR ENVELOPE PROTEIN EXPRESSION AT THE CELL SURFACE. DARS IS THE CYTOPLASMIC ASPARTYL TRNA SYNTHETASE, AND PART OF THE DYNAMIC MULTI-TRNA SYNTHETASE COMPLEX (MSC). ITS DEPLETION PHENOTYPE SUGGESTS THAT DARS PLAYS A ROLE IN STEPS OTHER THAN PROTEIN SYNTHESIS, PERHAPS INVOLVING THE MSC. YWHAB IS A MEMBER OF THE FAMILY OF 14-3-3 ADAPTOR PROTEINS, WHICH CAN REGULATE PROTEIN-PROTEIN INTERACTIONS AND PROTEIN MODIFICATIONS. WE WILL USE OUR ESTABLISHED PANEL OF ASSAYS TO DEFINE THE ROLE OF DARS AND YWHAB IN THE VIRUS EXIT PATHWAY. 2. DEFINE THE ROLE OF NOVEL HOST PROTEINS IN EARLY STEPS IN THE ALPHAVIRUS LIFE CYCLE. DEPLETION OF TWO HOST PROTEINS INHIBITED BOTH VIRUS SPREAD AND PRIMARY INFECTION, BUT DID NOT INHIBIT VIRAL RNA REPLICATION. WE WILL PERFORM MECHANISTIC STUDIES TO DEFINE THE DIFFERENTIAL ROLES OF RAB1B AND B SPECTRIN IN VIRUS INFECTION. THE RESULTS OF THESE STUDIES WILL PROVIDE FUNDAMENTAL INFORMATION ON HOST PROTEINS INVOLVED IN THE ALPHAVIRUS LIFE CYCLE, AND POTENTIAL NEW TARGETS FOR ANTIVIRAL STRATEGIES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 2/5/26 | ||
| Not listed | $210.0k | 4/8/25 | ||
| Not listed | $210.0k | 4/8/25 | ||
| Not listed | $0 | 12/5/24 | ||
| Not listed | $0 | 12/5/24 |